Recombinant Salmonella choleraesuis Fumarate reductase subunit C (frdC)

What is the biochemical role of frdC in Salmonella choleraesuis metabolism?

Fumarate reductase subunit C (frdC) is a hydrophobic, membrane-associated component of the fumarate reductase complex in Salmonella. It facilitates anaerobic respiration by transferring electrons from quinones to fumarate, enabling the bacterium to generate ATP under low-oxygen conditions . This enzyme is critical for bacterial survival in oxygen-limited environments, such as during host colonization or intracellular persistence.

How is recombinant frdC produced for research purposes?

Recombinant frdC is typically expressed in heterologous hosts like E. coli using plasmid-based systems. The process involves:

• Cloning: Amplification of the frdC gene from S. choleraesuis genomic DNA and insertion into expression vectors (e.g., pET or pGEX).

• Induction: Use of inducers like IPTG or arabinose to trigger protein synthesis.

• Purification: Affinity chromatography (e.g., His-tag or GST-tag systems) followed by refolding to restore activity .

What are the challenges in optimizing recombinant frdC production?

Key challenges include:

How can frdC be used as a vaccine antigen?

• Immune Evasion: S. choleraesuis often shows restricted host range, limiting cross-protection.

• Adjuvant Dependency: Requires co-administration with adjuvants (e.g., OMVs) to enhance mucosal immunity .

• Delivery Platforms: Attenuated Salmonella vectors (e.g., ΔaroA or ΔsopB strains) can deliver frdC to lymphoid tissues, eliciting both humoral and cellular responses .

What methods assess the structural integrity of recombinant frdC?

Structural validation is critical for functional studies. Common approaches include:

• Circular Dichroism (CD) Spectroscopy: Measures α-helix/β-sheet content to confirm proper folding .

• Cryo-EM or X-ray Crystallography: Resolves membrane-embedded topology and quinone-binding sites .

• Western Blotting: Detects post-translational modifications or tag retention (e.g., His-tag) .

How do conflicting data on frdC’s role in pathogenicity arise?

Discrepancies often stem from:

• Strain-Specific Differences: S. choleraesuis isolates vary in virulence factors and plasmid content, altering metabolic dependencies .

• Experimental Models: In vitro (e.g., broth cultures) vs. in vivo (e.g., mouse models) conditions may reveal divergent frdC expression patterns .

• Omic Analysis Bias: Proteomic studies may underrepresent membrane proteins like frdC due to solubility challenges .

What are the key considerations for frdC-based diagnostic assays?

How might frdC-targeted therapeutics be developed?

• Metabolic Inhibition: Small-molecule inhibitors of fumarate reductase could disrupt anaerobic respiration.

• CRISPR-Based Editing: Knockout of frdC in attenuated Salmonella vectors to enhance vaccine safety .

• Biomarker Discovery: frdC antibodies as indicators of S. choleraesuis infection in swine or humans .

What future directions are critical for frdC research?

• Structure-Function Mapping: Define frdC’s role in electron transport chains and redox balance .

• Host-Pathogen Interactions: Investigate frdC’s contribution to intracellular survival in macrophages .

• Multi-Omic Integration: Combine proteomic and metabolomic data to elucidate frdC’s regulatory networks .